Case Report: Safety and efficacy of tarlatamab for SCLC in a liver transplant recipient

Tarlatamab is a bispecific T-cell engager used for the treatment of small cell lung cancer (SCLC). Patients with a history of solid organ transplantation carry an elevated risk of malignancy yet are excluded from most clinical trials. We report the first case of Tarlatamab use in a liver transplant recipient with SCLC, resulting in marked tumor response and a favorable safety profile without evidence of graft rejection.

• Leonhardt, J.
• Pratschke, J.
• Behr, J.
• Gotschke, J.
• Jurmeister, P.
• Kauffmann-Guerrero, D.
• Klauschen, F.
• Lambrecht, L.
• Mras, P.
• Schneider, C.
• Resuli, B.
• Tufman, A.